Treatment of Hyperphosphatemia

Introduction to Hyperphosphatemia Management

• The treatment of hyperphosphatemia should focus on phosphate-lowering therapies only in cases of progressive or persistent hyperphosphatemia, not for prevention, and should include dietary phosphate restriction, phosphate binders, and addressing underlying causes, as recommended by the Kidney International guidelines 1, 2

Dietary Phosphate Restriction

• Limiting dietary phosphate intake is recommended as a first-line approach for treating hyperphosphatemia, either alone or in combination with other treatments, according to the Kidney International guidelines 2, 3
• Animal-based phosphate is absorbed at 40-60%, whereas plant-based phosphate (associated with phytates) is less absorbable (20-50%), as noted in the Kidney International journal 3
• Inorganic phosphate in food additives has higher absorption, highlighting the importance of considering phosphate source when making dietary recommendations, as stated in the Kidney International guidelines 3

Phosphate Binders

When to Initiate Phosphate Binders

• Phosphate-lowering therapies should only be initiated in cases of progressive or persistent hyperphosphatemia, not for prevention, as recommended by the Annals of Internal Medicine guidelines 4, 5
• Normophosphatemia is not an indication to start phosphate-lowering treatments, according to the Annals of Internal Medicine and Kidney International guidelines 6, 1

Types of Phosphate Binders

• Calcium acetate or calcium carbonate are effective phosphate binders but should be used with caution, as stated in the Annals of Internal Medicine guidelines 7
• Restrict the dose of calcium-based phosphate binders to avoid excess calcium exposure, which may be harmful across all GFR categories of CKD, as noted in the Annals of Internal Medicine guidelines 7

Special Considerations

• For patients with hyperphosphatemia and elevated PTH, addressing modifiable factors including vitamin D deficiency may be beneficial, as recommended by the Annals of Internal Medicine guidelines 5
• If hyperphosphatemia develops during treatment of hypocalcemia, consider phosphate binders, according to the Praxis Medical Insights guidelines, although this is not the preferred source, it is included for completeness 8

Potential Pitfalls and Caveats

• Excess exposure to calcium from calcium-based binders may be harmful across all GFR categories of CKD, as noted in the Annals of Internal Medicine guidelines 6, 7

Primary Treatment for Hyperphosphatemia

Stepwise Treatment Algorithm

• The American Journal of Kidney Diseases recommends limiting dietary phosphate intake to 800-1,000 mg/day, adjusted for protein needs, as the initial approach for all patients with elevated phosphorus levels 9
• For CKD Stages 3-4, the American Journal of Kidney Diseases suggests starting with calcium-based phosphate binders when serum phosphorus exceeds 4.6 mg/dL despite dietary restriction 9
• The American Journal of Kidney Diseases advises limiting elemental calcium from binders to ≤1,500 mg/day, with total calcium intake (including dietary) not exceeding 2,000 mg/day 9
• For CKD Stage 5 (Dialysis Patients), the American Journal of Kidney Diseases recommends either calcium-based binders or non-calcium binders as primary therapy, targeting serum phosphorus between 3.5-5.5 mg/dL 9
• The American Journal of Kidney Diseases suggests avoiding calcium-based binders entirely if severe vascular or soft-tissue calcifications are present 9
• For severe hyperphosphatemia (>7.0 mg/dL), the American Journal of Kidney Diseases recommends using aluminum-based binders short-term (4 weeks maximum, single course only), then switching to other agents 9
• If hyperphosphatemia persists (>5.5 mg/dL) despite monotherapy, the American Journal of Kidney Diseases advises combining calcium-based and non-calcium-based binders 9
• The American Journal of Kidney Diseases recommends ensuring adequate phosphate removal through dialysis, considering more frequent or longer dialysis sessions if hyperphosphatemia remains uncontrolled despite binders 9
• The American Journal of Kidney Diseases suggests maintaining corrected total serum calcium in the normal range, preferably 8.4-9.5 mg/dL (lower end of normal) for dialysis patients 9
• The American Journal of Kidney Diseases advises not exceeding 1,500 mg/day of elemental calcium from binders alone, as this increases risk of hypercalcemia and vascular calcification 9
• The American Journal of Kidney Diseases recommends not using calcium-based binders in hypercalcemic patients or those with suppressed PTH (<150 pg/mL), as this worsens outcomes 9
• The American Journal of Kidney Diseases suggests that dietary phosphate restriction alone is usually insufficient in most CKD patients, requiring the addition of binders 9